Here, we showed that combining HDAC and BRD inhibition reduced the viability of colon cancer cells markedly, whereas normal colonic epithelial cells were more resistant (Figure 4D,E and Figure S3), providing an avenue for selective toxicity mechanisms via differential drug uptake or metabolism [14]. This evidence concerns the gene HDAC9 and malignant colon neoplasm.